BioSpace News Archive

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023.

eFFECTOR Therapeutics, Inc. today announced new positive interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC).

Milestone Scientific Inc. today reported it has commenced commercial sales of CompuFlo® disposables for use in neurostimulation spinal cord stimulator implantation procedures at the University of Texas Medical Branch (UTMB) Health Clear Lake Campus Hospital.

Intensity Therapeutics, Inc. today announced that safety, tolerability, efficacy and immune activation data from the company’s Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS). Information on the presentation is below.

MEDSIR, a global leader in oncology research, today presented significant breakthroughs in the fight against aggressive breast cancer at the 46th San Antonio Breast Cancer Symposium (SABCS) that have the potential to transform the lives of breast cancer patients.

Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.

Novartis today announced results from an updated invasive disease-free survival (iDFS) analysis of the pivotal Phase III NATALEE trial, with a median follow-up of 33.3 months and following Kisqali® (ribociclib) treatment completion by 78.3% of patients.

The Board of Directors of GE HealthCare Technologies Inc. declared a cash dividend of $0.03 per share of Common Stock for the fourth quarter of 2023 payable on February 15, 2024 to all shareholders of record as of January 16, 2024.

Omeza® presented in vivo data showing that OCM™ alone significantly reduced methicillin-resistant staphylococcus aureus and pseudomonas aeruginosa bacterial counts and accelerated the formation of new tissue in MRSA-infected wounds, outperforming a comparator treatment and a control group.

Terran Biosciences, Inc. has received notice of allowance from the United States Patent and Trademark Office (USPTO) for four US patents covering a number of breakthroughs in the psychedelic therapeutic space.